1
Total investments
0
Early stage
0
Mid stage
0
Late stage
7y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Member of the Board
Jun 2019
Igenomix is a medical testing laboratory specializing in reproductive genetic services.
We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.
In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services for IVF clinics, founded in 2011. Together we create Vitolife Group, a global leader in reproductive health. By combining Igenomix’s portfolio of reproductive genetic testing services with Vitrolife’s best-in-class IVF device portfolio, we support clinics and patients across the fertility journey.
Based on science and advanced research capabilities, our aim is to deliver products and services for the entire fertility journey, providing consistent performance and guaranteed quality. We are a sustainable market leader and aim to be the preferred partner to the fertility clinics by providing superior products and services. Currently, Vitrolife Group are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 110 countries, through our own presence in 30 countries, and a network of distributors.
Our vision is to fulfil the dream of having a healthy baby, and we achieve this by supporting our customers in delivering successful treatment outcomes. We are your committed partner for the IVF journey. We can help you maximise success. – Together. All the way.
The Vitrolife AB (publ) share is listed on Nasdaq Stockholm.
Experience · 1 entries
All (1)
Investments (1)
Board (1)
2019
Member of the Board
Jun 2019
Igenomix is a medical testing laboratory specializing in reproductive genetic services.
We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.
In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services for IVF clinics, founded in 2011. Together we create Vitolife Group, a global leader in reproductive health. By combining Igenomix’s portfolio of reproductive genetic testing services with Vitrolife’s best-in-class IVF device portfolio, we support clinics and patients across the fertility journey.
Based on science and advanced research capabilities, our aim is to deliver products and services for the entire fertility journey, providing consistent performance and guaranteed quality. We are a sustainable market leader and aim to be the preferred partner to the fertility clinics by providing superior products and services. Currently, Vitrolife Group are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 110 countries, through our own presence in 30 countries, and a network of distributors.
Our vision is to fulfil the dream of having a healthy baby, and we achieve this by supporting our customers in delivering successful treatment outcomes. We are your committed partner for the IVF journey. We can help you maximise success. – Together. All the way.
The Vitrolife AB (publ) share is listed on Nasdaq Stockholm.